Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK) HKSE

5.75

-0.15(-2.54%)

Updated at May 13 04:08PM

Currency In HKD

Key Executives

Name	Title	Pay	Year Born
Yinxiang Wang	Founder, Co-CEO & Executive Chairman	4.27M	1965
Andrea Wang-Gillam	Co-CEO, Executive VP, Chief Medical Officer and Global Head of R&D	0	1971
Xiaojie Wang	Executive Director & President of Administration	2.82M	1965
Yunyan Hu	Executive Vice President & Executive Director	3M	1962
Haijun Wang	Senior Vice President of Information & Data Management	0	N/A
Yanping Wang	Executive Vice President of Non-Clinical R&D	0	N/A
Yuli Ding	Executive Vice President of Clinical Development	0	N/A
Ming Fai Chung	Joint Company Secretary	0	1980
Qing Xue	Joint Company Secretary	0	1989
Tao Yang	Vice President of Human Resources	0	N/A

Name

Title

Pay

Year Born

Yinxiang Wang

Founder, Co-CEO & Executive Chairman

4.27M

1965

Andrea Wang-Gillam

Co-CEO, Executive VP, Chief Medical Officer and Global Head of R&D

1971

Xiaojie Wang

Executive Director & President of Administration

2.82M

1965

Yunyan Hu

Executive Vice President & Executive Director

1962

Haijun Wang

Senior Vice President of Information & Data Management

N/A

Yanping Wang

Executive Vice President of Non-Clinical R&D

N/A

Yuli Ding

Executive Vice President of Clinical Development

N/A

Ming Fai Chung

Joint Company Secretary

1980

Qing Xue

Joint Company Secretary

1989

Tao Yang

Vice President of Human Resources

N/A

Description

Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company's lead drug development programs include two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors comprising JAB-3312 and JAB-3068 for the treatment of esophageal cancer; JAB-8263, a small molecule inhibitor of BET family proteins regulating MYC transcription to treat various cancers; and JAB-21822, an oral small molecule targeting mutant KRAS G12C protein. It is also develops JAB-BX102, a humanized inhibitory antibody against human CD73 for the treatment of PD-1 resistant cancer; JAB-6343, an inhibitor that targets fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma with FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, a tumor metabolic pathway for the treatment of solid tumors; and JAB-BX300, a molecule antibody targeting RAS pathway to treat pancreatic and other solid tumors with KRAS mutations. The company has a strategic collaboration with AbbVie Ireland Unlimited Company to develop and commercialize SHP2 inhibitors. Jacobio Pharmaceuticals Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, China.